Biological activity of the G-quadruplex ligand RHPS4 (3, 11-difluoro-6,8,13-trimethyl-8H-quino[4,3,2-kl]acridinium methosulfate) is associated with telomere capping alteration

Molecular Pharmacology

Volumn 66, Issue 5, 2004, Pages 1138-1146

  Leonetti, Carlo ^a   Amodei, Sarah ^a   D'Angelo, Carmen ^a   Rizzo, Angela ^a   Benassi, Barbara ^a   Antonelli, Anna ^b   Elli, Raffaella ^b   Stevens, Malcolm F G ^c   D'Incalci, Maurizio ^d   Zupi, Gabriella ^a   Biroccio, Annamaria ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^d MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

3,11 DIFLUORO 6,8,13 TRIMETHYL 8H QUINO[4,3,2 KL]ACRIDINIUM METHOSULFATE; ACRIDINE DERIVATIVE; BETA GALACTOSIDASE; LIGAND; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL PROLIFERATION; CELL SIZE; CYTOPLASM; DOSE RESPONSE; ENZYME ACTIVITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; SENESCENCE; STRUCTURE ACTIVITY RELATION; TELOMERE; TELOPHASE;

ACRIDINES; APOPTOSIS; CELL AGING; CELL CYCLE; HUMANS; LIGANDS; MELANOMA; TELOMERE; TUMOR CELLS, CULTURED;

EID: 6944239985     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.001537     Document Type: Article

References (38)

1. Akiyama M, Yamada O, Kanda N, Akita S, Kawano T, Ohno T, Mizoguchi H, Eto Y, Anderson KC, and Yamada H (2002) Telomerase overexpression in K562 leukemia cells protects against apoptosis by serum deprivation and double-stranded DNA break inducing agents, but not against DNA synthesis inhibitors. Cancer Lett 178:187-197.
2. Biroccio A, Amodei S, Benassi B, Scarsella M, Cianciulli A, Mottolese M, Del Bufalo D, Leonetti C, and Zupi G (2002) Reconstitution of hTERT restores tumorigenicity in melanoma-derived c-Myc low-expressing clones. Oncogene 21:3011-3019.
3. Biroccio A, Amodei S, Antonelli A, Benassi B, and Zupi G (2003a) Inhibition of c-Myc oncoprotein limits the growth of human melanoma cells by inducing cellular crisis. J Biol Chem 278:35693-35701.
4. Biroccio A, Gabellini C, Amodei S, Benassi B, Del Bufalo D, Elli R, Antonelli A, D'Incalci M, and Zupi G (2003b) Telomere dysfunction increases cisplatin and ecteinascidin-743 sensitivity of melanoma cells. Mol Pharmacol 63:632-638.
5. Blackburn EH (2000) Telomere states and cell fates. Nature (Lond) 408:53-56.
6. Bodnar AG, Ouellette M, Frolkis M, Holt SE, Chiu CP, Morin GB, Harley CB, Shay JW, Lichtsteiner S, and Wright WE (1998) Extension of life-span by introduction of telomerase into normal human cells. Science (Wash DC) 279:349-352.
7. Caprio V, Guyen B, Opoku-Boahen Y, Mann J, Gowan SM, Kelland LM, Read MA, and Neidle S (2000) A novel inhibitor of human telomerase derived from 10H-indolo[3,2-b]quinoline. Bioorg Med Chem Lett 10:2063-2066.
8. Damm K, Hemmann U, Garin-Chesa P, Hauel N, Kauffmann I, Priepke H, Niestroj C, Daiber C, Enenkel B, Guilliard B, et al. (2001) A highly selective telomerase inhibitor limiting human cancer cell proliferation. EMBO J 20:6958-6968.
9. Fedoroff OY, Salazar M, Han H, Chemeris VV, Kerwin SM, and Hurley LH (1998) NMR-Based model of a telomerase-inhibiting compound bound to G-quadruplex DNA. Biochemistry 37:12367-12374.
10. Gavathiotis E, Heald RA, Stevens MFG, and Searle MS (2003) Drug recognition and stabilisation of the parallel-stranded DNA quadruplex d(TTAGGGT)4 containing the human telomeric repeat. J Mol Biol 334:25-36.
11. Gomez D, Aouali N, Londono-Vallejo A, Lacroix L, Megnin-Chanet F, Lemarteleur T, Douarre C, Shin-ya K, Mailliet P, Trentesaux C, et al. (2003) Resistance to the short-term antiproliferative activity of the G-quadruplex ligand 12459 is associated with telomerase overexpression and telomere-capping alteration. J Biol Chem 278:50554-50562.
12. Gowan SM, Heald R, Stevens MFG, and Kelland LR (2001) Potent inhibition of telomerase by small-molecule pentacyclic acridines capable of interacting with G-quadruplexes. Mol Pharmacol 60:981-988.
13. Gowan SM, Harrison JR, Patterson L, Valenti M, Read MA, Neidle S, and Kelland LR (2002) A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo antitumor activity. Mol Pharmacol 61:1154-1162.
14. Hahn WC, Stewart SA, Brooks MW, York SG, Eaton E, Kurachi A, Beijersbergen RL, Knoll JH, Meyerson M, and Weinberg RA (1999) Inhibition of telomerase limits the growth of human cancer cells. Nat Med 5:1164-1170.
15. Harrison RJ, Gowan SM, Kelland LR, and Neidle S (1999) Human telomerase inhibition by substituted acridine derivatives. Bioorg Med Chem Lett 9:2463-2468.
16. Heald RA, Modi C, Cookson JC, Hutchinson I, Laughton CA, Gowan SM, Kelland LR, and Stevens MFG (2002) Antitumor polycyclic acridines. 8. (1) Synthesis and telomerase-inhibitory activity of methylated pentacyclic acridinium salts. J Med Chem 45:590-597.
17. Izbicka E, Wheelhouse RT, Raymond E, Davidson KK, Lawrence RA, Sun D, Windle BE, Hurley LH, and Von Hoff DD (1999) Effects of cationic porphyrins as G-quadruplex interactive agents in human tumor cells. Cancer Res 58:639-644.
18. Karlseder J, Broccoli D, Dai Y, Hardy S, and de Lange T (1999) p53- and ATM-dependent apoptosis induced by telomeres lacking TRF2. Science (Wash DC) 283:1321-1325.
19. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Thor AD, and Blackburn EH (2001) A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci USA 98:7982-7897.
20. Kim MY, Gleason-Guzman M, Izbicka E, Nishioka D, and Hurley LH (2003) The different biological effects of telomestatin and TMPyP4 can be attributed to their selectivity for interaction with intramolecular or intermolecular G-quadruplex structures. Cancer Res 63:3247-3256.
21. Morin GB (1989) The human telomere terminal transferase enzyme is a ribonucleoprotein that synthesizes TTAGGG repeats. Cell 59:521-529.
22. Mukai S, Kondo Y, Koga S, Komata T, Barna BP, and Kondo S (2000) 2-5A antisense telomerase RNA therapy for intracranial malignant gliomas. Cancer Res 60:4461-4467.
23. Naasani I, Seimiya H, Yamori T, and Tsuruo T (1999) FJ5002: a potent telomerase inhibitor identified by exploiting the disease-oriented screening program with COMPARE analysis. Cancer Res 59:4004-4011.
24. Norton JC, Piatyszek MA, Wright WE, Shay JW, and Corey DR (1996) Inhibition of human telomerase activity by peptide nucleic acids. Nat Biotechnol 14:615-619.
25. Oh H, Taffet GE, Youker KA, Entman ML, Overbeek PA, Michael LH, and Schneider MD (2001) Telomerase reverse transcriptase promotes cardiac muscle cell proliferation, hypertrophy and survival. Proc Natl Acad Sci USA 98:10308-10313.
26. Perry PJ, Gowan SM, Reszka AP, Polucci P, Jenkins TC, Kelland LR, and Neidle S (1998) 1,4- and 2,6-disubstituted amidoanthracene-9,10-dione derivatives as inhibitors of human telomerase. J Med Chem 41:3253-3260.
27. Perry PJ, Gowan SM, Read MA, Kelland LR, and Neidle S (1999a) Design, synthesis and evaluation of human telomerase inhibitors based upon a tetracyclic structural motif. Anticancer Drug Des 14:373-382.
28. Perry PJ, Read MA, Davies RT, Gowan SM, Reszka AP, Wood AA, Kelland LR, and Neidle S (1999b) 2,7-Disubstituted amidofluorenone derivatives as inhibitors of human telomerase. J Med Chem 42:2679-2684.
29. Pitts AE and Corey DR (1998) Inhibition of human telomerase by 2′-O-methyl-RNA. Proc Natl Acad Sci USA 95:11549-11554.
30. Rangan A, Fedoroff OY, and Hurley LH (2001) Induction of duplex to G-quadruplex transition in the c-myc promoter region by a small molecule. J Biol Chem 276:4640-4646.
31. Riou JF, Guittat L, Mailliet P, Laoui A, Renou E, Petitgenet O, Megnin-Chanet F, Helene C, and Mergny JL (2002) Cell senescence and telomere shortening induced by a new series of specific G-quadruplex DNA ligands. Proc Natl Acad Sci USA 89:2672-2677.
32. Sharma S, Raymond E, Soda H, Sun D, Hilsenbeck SG, Sharma A, Izbicka E, Windle B, and Von Hoff DD (1997) Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 8:1063-1074.
33. Shay JW and Bacchetti S (1997) A survey of telomerase activity in human cancer. Eur J Cancer 33:787-791.
34. Shi DF, Wheelhouse RT, Sun D, and Hurley LH (2001) Quadruplex-interactive agents as telomerase inhibitors: synthesis of porphyrins and structure-activity relationship for the inhibition of telomerase. J Med Chem 44:4509-4523.
35. Sun D, Thompson B, Cathers BE, Salazar M, Kerwin SM, Trent JO, Jenkins TC, Neidle S, and Hurley LH (1997) Inhibition of human telomerase by a G-quadruplex-interactive compound. J Med Chem 40:2113-2116.
36. van Steensel B, Smogorzewska A, and de Lange T (1998) TRF2 protects human telomeres from end-to-end fusions. Cell 92:401-413.
37. Wang J, Xie LY, Allan S, Beach D, and Hannon GJ (1998) Myc activates telomerase. Genes Dev 12:1769-1774.
38. Zahler AM, Williamson JE, Cech TR, and Prescott DM (1991) Inhibition of telomerase by G-quartet DNA structures. Nature (Lond) 350:718-720.